{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T04:34:52Z","timestamp":1774931692105,"version":"3.50.1"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,4,22]],"date-time":"2024-04-22T00:00:00Z","timestamp":1713744000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,4,22]],"date-time":"2024-04-22T00:00:00Z","timestamp":1713744000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Genet Genomics"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s00438-024-02140-7","type":"journal-article","created":{"date-parts":[[2024,4,22]],"date-time":"2024-04-22T20:29:32Z","timestamp":1713817772000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Construction of immune-related gene pairs signature to predict the overall survival of multiple myeloma patients based on whole bone marrow gene expression profiling"],"prefix":"10.1007","volume":"299","author":[{"given":"Farideh","family":"Jafari-Raddani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zeinab","family":"Davoodi-Moghaddam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8029-4920","authenticated-orcid":false,"given":"Davood","family":"Bashash","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,4,22]]},"reference":[{"issue":"9","key":"2140_CR1","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1164\/rccm.201703-0660OC","volume":"197","author":"D Ajona","year":"2018","unstructured":"Ajona D et al (2018) Blockade of the complement C5a\/C5aR1 axis impairs lung cancer bone metastasis by CXCL16-mediated effects. Am J Respir Crit Care Med 197(9):1164\u20131176","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"2140_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13059-017-1349-1","volume":"18","author":"D Aran","year":"2017","unstructured":"Aran D, Hu Z, Butte AJ (2017) xCell: digitally portraying the tissue cellular heterogeneity landscape. Genome Biol 18(1):1\u201314","journal-title":"Genome Biol"},{"issue":"2","key":"2140_CR3","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1007\/s12026-014-8516-1","volume":"58","author":"S Bhattacharya","year":"2014","unstructured":"Bhattacharya S et al (2014) ImmPort: disseminating data to the public for the future of immunology. Immunol Res 58(2):234\u2013239","journal-title":"Immunol Res"},{"issue":"4","key":"2140_CR4","first-page":"1008","volume":"4","author":"H Black","year":"2021","unstructured":"Black H, Glavey S (2021) Gene expression profiling as a prognostic tool in multiple myeloma. Cancer Drug Resistance 4(4):1008","journal-title":"Cancer Drug Resistance"},{"issue":"12","key":"2140_CR5","doi-asserted-by":"publisher","first-page":"e511","DOI":"10.1038\/bcj.2016.118","volume":"6","author":"C Botta","year":"2016","unstructured":"Botta C et al (2016) A gene expression inflammatory signature specifically predicts multiple myeloma evolution and patients survival. Blood Cancer J 6(12):e511\u2013e511","journal-title":"Blood Cancer J"},{"key":"2140_CR6","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1007\/s00262-019-02422-9","volume":"68","author":"J Burks","year":"2019","unstructured":"Burks J et al (2019) ISG15 pathway knockdown reverses pancreatic cancer cell transformation and decreases murine pancreatic tumor growth via downregulation of PDL-1 expression. Cancer Immunol Immunother 68:2029\u20132039","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"2140_CR7","doi-asserted-by":"publisher","first-page":"553","DOI":"10.4049\/jimmunol.167.1.553","volume":"167","author":"JD Campbell","year":"2001","unstructured":"Campbell JD et al (2001) Suppression of IL-2-induced T cell proliferation and phosphorylation of STAT3 and STAT5 by tumor-derived TGF\u03b2 is reversed by IL-15. J Immunol 167(1):553\u2013561","journal-title":"J Immunol"},{"key":"2140_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.594775","volume":"11","author":"R-H Chen","year":"2020","unstructured":"Chen R-H et al (2020) Tumor cell-secreted ISG15 promotes tumor cell migration and immune suppression by inducing the macrophage M2-like phenotype. Front Immunol 11:594775","journal-title":"Front Immunol"},{"issue":"7","key":"2140_CR9","doi-asserted-by":"publisher","first-page":"646","DOI":"10.3390\/life11070646","volume":"11","author":"C-L Chou","year":"2021","unstructured":"Chou C-L et al (2021) CTSE overexpression is an adverse prognostic factor for survival among rectal cancer patients receiving CCRT. Life 11(7):646","journal-title":"Life"},{"issue":"1","key":"2140_CR10","doi-asserted-by":"publisher","first-page":"79","DOI":"10.3324\/haematol.2012.067272","volume":"98","author":"RJP de Magalh\u00e3es","year":"2013","unstructured":"de Magalh\u00e3es RJP et al (2013) Analysis of the immune system of multiple myeloma patients achieving long-term disease control by multidimensional flow cytometry. Haematologica 98(1):79","journal-title":"Haematologica"},{"issue":"19","key":"2140_CR11","doi-asserted-by":"publisher","first-page":"8619","DOI":"10.7150\/thno.45058","volume":"10","author":"P Ding","year":"2020","unstructured":"Ding P et al (2020) C5aR1 is a master regulator in colorectal tumorigenesis via immune modulation. Theranostics 10(19):8619","journal-title":"Theranostics"},{"issue":"1","key":"2140_CR12","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1038\/nri704","volume":"2","author":"L Gorelik","year":"2002","unstructured":"Gorelik L, Flavell RA (2002) Transforming growth factor-\u03b2 in T-cell biology. Nat Rev Immunol 2(1):46\u201353","journal-title":"Nat Rev Immunol"},{"issue":"5","key":"2140_CR13","doi-asserted-by":"publisher","first-page":"2246","DOI":"10.1172\/JCI73639","volume":"124","author":"A Gros","year":"2014","unstructured":"Gros A et al (2014) PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors. J Clin Investig 124(5):2246\u20132259","journal-title":"J Clin Investig"},{"issue":"4","key":"2140_CR14","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/nm.4051","volume":"22","author":"A Gros","year":"2016","unstructured":"Gros A et al (2016) Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients. Nat Med 22(4):433\u2013438","journal-title":"Nat Med"},{"issue":"8","key":"2140_CR15","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1038\/leu.2016.388","volume":"31","author":"S Hipp","year":"2017","unstructured":"Hipp S et al (2017) A novel BCMA\/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo. Leukemia 31(8):1743\u20131751","journal-title":"Leukemia"},{"issue":"1","key":"2140_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40425-017-0256-z","volume":"5","author":"W Jing","year":"2017","unstructured":"Jing W et al (2017) Adoptive cell therapy using PD-1+ myeloma-reactive T cells eliminates established myeloma in mice. J Immunother Cancer 5(1):1\u201311","journal-title":"J Immunother Cancer"},{"issue":"3","key":"2140_CR17","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1111\/bjh.12544","volume":"163","author":"YJ Kang","year":"2013","unstructured":"Kang YJ et al (2013) Identification of human leucocyte antigen (HLA)-A* 0201-restricted cytotoxic T lymphocyte epitopes derived from HLA-DO \u03b2 as a novel target for multiple myeloma. Br J Haematol 163(3):343\u2013351","journal-title":"Br J Haematol"},{"issue":"7","key":"2140_CR18","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1158\/1078-0432.CCR-10-2081","volume":"17","author":"H-S Kim","year":"2011","unstructured":"Kim H-S et al (2011) Functional roles of Src and Fgr in ovarian carcinomafunctional roles of Src and Fgr in ovarian carcinoma. Clin Cancer Res 17(7):1713\u20131721","journal-title":"Clin Cancer Res"},{"issue":"11","key":"2140_CR19","doi-asserted-by":"publisher","first-page":"5109","DOI":"10.1182\/blood.V106.11.5109.5109","volume":"106","author":"M Kline","year":"2005","unstructured":"Kline M et al (2005) Identification of genes associated with increased bone marrow angiogenesis in multiple myeloma. Blood 106(11):5109","journal-title":"Blood"},{"issue":"11","key":"2140_CR20","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.1038\/leu.2012.127","volume":"26","author":"R Kuiper","year":"2012","unstructured":"Kuiper R et al (2012) A gene expression signature for high-risk multiple myeloma. Leukemia 26(11):2406\u20132413","journal-title":"Leukemia"},{"key":"2140_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2017.46","author":"SK Kumar","year":"2017","unstructured":"Kumar SK et al (2017) Multiple myeloma. Nat Rev Dis Primers. https:\/\/doi.org\/10.1038\/nrdp.2017.46","journal-title":"Nat Rev Dis Primers"},{"issue":"16","key":"2140_CR22","doi-asserted-by":"publisher","first-page":"4124","DOI":"10.3390\/cancers13164124","volume":"13","author":"B Lawal","year":"2021","unstructured":"Lawal B et al (2021) Pan-cancer analysis of immune complement signature C3\/C5\/C3AR1\/C5AR1 in association with tumor immune evasion and therapy resistance. Cancers 13(16):4124","journal-title":"Cancers"},{"issue":"2","key":"2140_CR23","first-page":"331","volume":"6","author":"F Li","year":"2016","unstructured":"Li F et al (2016) The increased excretion of urinary orosomucoid 1 as a useful biomarker for bladder cancer. Am J Cancer Res 6(2):331\u2013340","journal-title":"Am J Cancer Res"},{"issue":"2","key":"2140_CR24","doi-asserted-by":"publisher","first-page":"466","DOI":"10.21037\/tcr.2019.11.30","volume":"9","author":"Y Li","year":"2020","unstructured":"Li Y et al (2020) Clinical significance of PI3 and HLA-DOB as potential prognostic predicators for ovarian cancer. Transl Cancer Res 9(2):466\u2013476","journal-title":"Transl Cancer Res"},{"issue":"14","key":"2140_CR25","doi-asserted-by":"publisher","first-page":"2379","DOI":"10.1002\/sim.6079","volume":"33","author":"M Lorent","year":"2014","unstructured":"Lorent M, Giral M, Foucher Y (2014) A solution for evaluating the accuracy of a marker to predict disease-related mortality. Stat Med. 33(14):2379\u20132389","journal-title":"Stat Med."},{"issue":"6","key":"2140_CR26","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1046\/j.1365-2141.2003.04375.x","volume":"121","author":"B Maecker","year":"2003","unstructured":"Maecker B et al (2003) Viral antigen-specific CD8+ T-cell responses are impaired in multiple myeloma. Br J Haematol 121(6):842\u2013848","journal-title":"Br J Haematol"},{"key":"2140_CR27","doi-asserted-by":"publisher","unstructured":"Mamoor S (2020) The death receptor Fas (CD95) is differentially expressed in brain metastases in breast cancer. https:\/\/doi.org\/10.31219\/osf.io\/mtafu","DOI":"10.31219\/osf.io\/mtafu"},{"key":"2140_CR28","doi-asserted-by":"publisher","unstructured":"Mamoor S (2021) CD3d is differentially expressed in the lymph nodes of patients with metastatic breast cancer. https:\/\/doi.org\/10.31219\/osf.io\/5qf8d","DOI":"10.31219\/osf.io\/5qf8d"},{"issue":"1","key":"2140_CR29","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s13048-023-01097-2","volume":"16","author":"C Meijuan","year":"2023","unstructured":"Meijuan C, Meng X, Fang L, Qian W (2023) Synaptotagmin-like protein 1 is a potential diagnostic and prognostic biomarker in endometrial cancer based on bioinformatics and experiments. J Ovarian Res. 16(1):16. https:\/\/doi.org\/10.1186\/s13048-023-01097-2","journal-title":"J Ovarian Res."},{"key":"2140_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.625199","volume":"10","author":"T Moser-Katz","year":"2021","unstructured":"Moser-Katz T et al (2021) Game of bones: how myeloma manipulates its microenvironment. Front Oncol 10:625199","journal-title":"Front Oncol"},{"issue":"24","key":"2140_CR31","doi-asserted-by":"publisher","first-page":"2731","DOI":"10.1182\/blood.2020006540","volume":"136","author":"K Nakamura","year":"2020","unstructured":"Nakamura K, Smyth MJ, Martinet L (2020) Cancer immunoediting and immune dysregulation in multiple myeloma. Blood 136(24):2731\u20132740","journal-title":"Blood"},{"issue":"14","key":"2140_CR32","doi-asserted-by":"publisher","first-page":"7627","DOI":"10.3390\/ijms23147627","volume":"23","author":"P Neumeister","year":"2022","unstructured":"Neumeister P et al (2022) Targeting the microenvironment for treating multiple myeloma. Int J Mol Sci 23(14):7627","journal-title":"Int J Mol Sci"},{"issue":"7","key":"2140_CR33","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1182\/blood-2018-09-825331","volume":"133","author":"C Pawlyn","year":"2019","unstructured":"Pawlyn C, Davies FE (2019) Toward personalized treatment in multiple myeloma based on molecular characteristics. Blood 133(7):660\u2013675","journal-title":"Blood"},{"issue":"7","key":"2140_CR34","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/j.pan.2019.09.009","volume":"19","author":"C Pontious","year":"2019","unstructured":"Pontious C et al (2019) Cathepsin E expression and activity: role in the detection and treatment of pancreatic cancer. Pancreatology 19(7):951\u2013956","journal-title":"Pancreatology"},{"issue":"1","key":"2140_CR35","doi-asserted-by":"publisher","first-page":"8822","DOI":"10.1080\/21655979.2021.1987067","volume":"12","author":"L Qiong","year":"2021","unstructured":"Qiong L, Yin J (2021) Orosomucoid 1 promotes epirubicin resistance in breast cancer by upregulating the expression of matrix metalloproteinases 2 and 9. Bioengineered 12(1):8822\u20138832","journal-title":"Bioengineered"},{"issue":"10","key":"2140_CR36","first-page":"17140","volume":"8","author":"X Qiu","year":"2015","unstructured":"Qiu X et al (2015) ISG15 as a novel prognostic biomarker for hepatitis B virus-related hepatocellular carcinoma. Int J Clin Exp Med 8(10):17140","journal-title":"Int J Clin Exp Med"},{"issue":"18","key":"2140_CR37","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","volume":"380","author":"N Raje","year":"2019","unstructured":"Raje N et al (2019) Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma. N Engl J Med 380(18):1726\u20131737","journal-title":"N Engl J Med"},{"key":"2140_CR38","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.cellsig.2019.01.007","volume":"56","author":"AK Roseweir","year":"2019","unstructured":"Roseweir AK et al (2019) Src family kinases, HCK and FGR, associate with local inflammation and tumour progression in colorectal cancer. Cell Signal 56:15\u201322","journal-title":"Cell Signal"},{"issue":"sup1","key":"2140_CR39","doi-asserted-by":"publisher","first-page":"S83","DOI":"10.1517\/14712598.2013.799130","volume":"13","author":"M Rossi","year":"2013","unstructured":"Rossi M et al (2013) Immunologic microenvironment and personalized treatment in multiple myeloma. Expert Opin Biol Ther 13(sup1):S83\u2013S93","journal-title":"Expert Opin Biol Ther"},{"issue":"24","key":"2140_CR40","doi-asserted-by":"publisher","first-page":"7309","DOI":"10.1158\/0008-5472.CAN-14-1354","volume":"74","author":"B Sainz","year":"2014","unstructured":"Sainz B et al (2014) ISG15 is a critical microenvironmental factor for pancreatic cancer stem CellsISG15 and pancreatic cancer. Can Res 74(24):7309\u20137320","journal-title":"Can Res"},{"issue":"14","key":"2140_CR41","doi-asserted-by":"publisher","first-page":"7470","DOI":"10.3390\/ijms22147470","volume":"22","author":"AM Soliman","year":"2021","unstructured":"Soliman AM, Das S, Teoh SL (2021) Next-generation biomarkers in multiple myeloma: understanding the molecular basis for potential use in diagnosis and prognosis. Int J Mol Sci 22(14):7470","journal-title":"Int J Mol Sci"},{"issue":"1","key":"2140_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-022-01234-2","volume":"15","author":"M Swamydas","year":"2022","unstructured":"Swamydas M et al (2022) Deciphering mechanisms of immune escape to inform immunotherapeutic strategies in multiple myeloma. J Hematol Oncol 15(1):1\u201317","journal-title":"J Hematol Oncol"},{"issue":"9","key":"2140_CR43","first-page":"10975","volume":"8","author":"J Tao","year":"2015","unstructured":"Tao J et al (2015) Prognostic value of ISG15 mRNA level in drinkers with esophageal squamous cell cancers. Int J Clin Exp Pathol 8(9):10975","journal-title":"Int J Clin Exp Pathol"},{"issue":"9","key":"2140_CR44","doi-asserted-by":"publisher","first-page":"e448","DOI":"10.1016\/S2352-3026(19)30109-7","volume":"6","author":"SZ Usmani","year":"2019","unstructured":"Usmani SZ et al (2019) Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial. Lancet Haematol 6(9):e448\u2013e458","journal-title":"Lancet Haematol"},{"issue":"6","key":"2140_CR45","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1182\/blood-2015-10-646810","volume":"127","author":"NW van de Donk","year":"2016","unstructured":"van de Donk NW et al (2016) Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma. Blood 127(6):681\u2013695","journal-title":"Blood"},{"issue":"1","key":"2140_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-021-01162-7","volume":"14","author":"CT Wallington-Beddoe","year":"2021","unstructured":"Wallington-Beddoe CT, Mynott RL (2021) Prognostic and predictive biomarker developments in multiple myeloma. J Hematol Oncol 14(1):1\u201315","journal-title":"J Hematol Oncol"},{"issue":"1","key":"2140_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40246-019-0231-5","volume":"13","author":"M Went","year":"2019","unstructured":"Went M et al (2019) Transcriptome-wide association study of multiple myeloma identifies candidate susceptibility genes. Hum Genomics 13(1):1\u20138","journal-title":"Hum Genomics"},{"issue":"12","key":"2140_CR49","doi-asserted-by":"publisher","first-page":"4415","DOI":"10.1158\/1078-0432.CCR-05-0259","volume":"11","author":"PJ Wild","year":"2005","unstructured":"Wild PJ et al (2005) Gene expression profiling of progressive papillary noninvasive carcinomas of the urinary bladder. Clin Cancer Res 11(12):4415\u20134429","journal-title":"Clin Cancer Res"},{"issue":"40","key":"2140_CR50","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000031071","volume":"101","author":"G Wu","year":"2022","unstructured":"Wu G et al (2022) Bioinformatics analysis of the clinical significance of HLA class II in breast cancer. Medicine (baltimore) 101(40):e31071","journal-title":"Medicine (baltimore)"},{"issue":"3","key":"2140_CR51","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/s41417-020-00217-0","volume":"28","author":"J Xiong","year":"2021","unstructured":"Xiong J et al (2021) C3a and C5a facilitates the metastasis of myeloma cells by activating Nrf2. Cancer Gene Ther 28(3):265\u2013278","journal-title":"Cancer Gene Ther"},{"issue":"2","key":"2140_CR52","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1007\/s12094-022-02956-y","volume":"25","author":"D Xu","year":"2022","unstructured":"Xu D et al (2022) C5aR1 promotes the progression of colorectal cancer by EMT and activating Wnt\/\u03b2-catenin pathway. Clin Transl Oncol. 25(2):440\u2013446","journal-title":"Clin Transl Oncol."},{"issue":"1","key":"2140_CR53","doi-asserted-by":"publisher","first-page":"25","DOI":"10.2217\/imt-2019-0145","volume":"12","author":"Y Yang","year":"2020","unstructured":"Yang Y et al (2020) CD3D is associated with immune checkpoints and predicts favorable clinical outcome in colon cancer. Immunotherapy 12(1):25\u201335","journal-title":"Immunotherapy"},{"issue":"5","key":"2140_CR54","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1172\/JCI81516","volume":"126","author":"T Yokoyama","year":"2016","unstructured":"Yokoyama T et al (2016) MEIS1-mediated transactivation of synaptotagmin-like 1 promotes CXCL12\/CXCR4 signaling and leukemogenesis. J Clin Investig 126(5):1664\u20131678","journal-title":"J Clin Investig"},{"key":"2140_CR55","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.913670","author":"L Yuan","year":"2022","unstructured":"Yuan L et al (2022) Cd3d is an independent prognostic factor and correlates with immune infiltration in gastric cancer. Front Oncol. https:\/\/doi.org\/10.3389\/fonc.2022.913670","journal-title":"Front Oncol."},{"issue":"1","key":"2140_CR56","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-019-6169-0","volume":"20","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, Yu C (2020) Prognostic characterization of OAS1\/OAS2\/OAS3\/OASL in breast cancer. BMC Cancer 20(1):1\u201312","journal-title":"BMC Cancer"},{"key":"2140_CR57","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.649326","volume":"8","author":"C Zhang","year":"2021","unstructured":"Zhang C et al (2021) Three immune-related prognostic mRNAs as therapeutic targets for pancreatic cancer. Front Med 8:649326","journal-title":"Front Med"},{"issue":"1","key":"2140_CR58","doi-asserted-by":"publisher","DOI":"10.1042\/BSR20202898","volume":"41","author":"Z Zhu","year":"2021","unstructured":"Zhu Z et al (2021) Comprehensive analysis reveals a prognostic and therapeutic biomarker CD3D in the breast carcinoma microenvironment. Biosci Rep 41(1):BSR20202898. https:\/\/doi.org\/10.1042\/BSR20202898","journal-title":"Biosci Rep"}],"container-title":["Molecular Genetics and Genomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00438-024-02140-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00438-024-02140-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00438-024-02140-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,22]],"date-time":"2024-04-22T20:29:49Z","timestamp":1713817789000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00438-024-02140-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,22]]},"references-count":57,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["2140"],"URL":"https:\/\/doi.org\/10.1007\/s00438-024-02140-7","relation":{},"ISSN":["1617-4615","1617-4623"],"issn-type":[{"value":"1617-4615","type":"print"},{"value":"1617-4623","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,22]]},"assertion":[{"value":"23 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"47"}}